SUMITOMO PHARMA CO LTD
- Country
- π―π΅Japan
- Ownership
- Public, Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- $1.8B
First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP
- Conditions
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT06460064
- Locations
- π§πͺ
Center for Vaccinology, Gent, Corneel Heymanslaan 10, Belgium
A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT05435729
- Locations
- π―π΅
Nippon Medical School Hospital, Bunkyo, Tokyo, Japan
A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT05359081
- Locations
- π―π΅
Sangubashi Kokorono Clinic, Shibuya-ku, Tokyo, Japan
π―π΅Ryokuwakai Stresscare Hibiya Clinic, Chiyoda-ku, Tokyo, Japan
π―π΅Kuramitsu Hospital, Fukuoka-shi, Fukuoka, Japan
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 83
- Registration Number
- NCT04825860
- Locations
- π―π΅
NHO Ryukyu Hospital, Kunigami, Okinawa, Japan
π―π΅Asakayama Hospital, Sakai, Osaka, Japan
π¨π³Shanghai Mental Health Center, Shanghai, Shanghai, China
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT04325737
- Locations
- π―π΅
Mental Support SOYOKAZE Hospital, Ueda-shi, Nagano-Ken, Japan
π―π΅Shiranui Hospital, Omuta-shi, Fukuoka-Ken, Japan
π―π΅Nishiurakai Keihan Hospital, Osaka-Fu, Moriguchi-shi, Japan
A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03563560
- Locations
- π―π΅
Fukui University Hospital, Yoshida-gun, Fukui, Japan
π―π΅Chugoku Central Hospital, Fukuyama, Hiroshima, Japan
π―π΅Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT03370640
- Locations
- π―π΅
Mental Support SOYOKAZE Hospital, Ueda, Nagano, Japan
π―π΅Showa University Karasuyama Hospital, Setagaya-Ku, Tokyo, Japan
π―π΅Yuge Hospital, Kumamoto, Japan
A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT02750891
- Locations
- π―π΅
National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan
π―π΅Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
π―π΅Osaka University Hospital, Suita, Osaka, Japan
A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 4
- Registration Number
- NCT02641873
- Locations
- π―π΅
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
π―π΅National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Study of DSP-7888 in Patients With Myelodysplastic Syndrome
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT02436252
- Locations
- π―π΅
Kindai University Hospital, Osakasayama, Osaka, Japan
π―π΅National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
π―π΅Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan